Overview of emerging pharmacologic agents for acute heart failure syndromes (Q37086309)

18 August 2017

1 reference

title

Overview of emerging pharmacologic agents for acute heart failure syndromes (English)

1 reference

Acute decompensated heart failure

18 August 2017

0 references

1 reference

1 reference

11

Kenneth Dickstein

0 references

Mihai Gheorghiade

12

object named as

Mihai Gheorghiade

1 reference

18 August 2017

8

Faiez Zannad

1 reference

18 August 2017

3

Gerasimos Filippatos

1 reference

18 August 2017

2

Alexandre Mebazaa

1 reference

18 August 2017

6

Adriaan A Voors

1 reference

18 August 2017

Leonardo De Luca

1

1 reference

18 August 2017

John T Parissis

4

1 reference

18 August 2017

Michael Böhm

5

1 reference

18 August 2017

Markku Nieminen

7

1 reference

18 August 2017

Andrew Rhodes

9

1 reference

18 August 2017

Ali El-Banayosy

10

1 reference

18 August 2017

1 February 2008

1 reference

European Journal of Heart Failure

18 August 2017

1 reference

18 August 2017

10

1 reference

18 August 2017

201-213

1 reference

18 August 2017

2

1 reference

Acute heart failure syndromes: current state and framework for future research

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

An introduction to acute heart failure syndromes: definition and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Review of current and investigational pharmacologic agents for acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Vasopressin: a therapeutic target in congestive heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Adenosine A1 receptor antagonists and the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Renal effects of adenosine A1-receptor antagonists in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

The renal urodilatin system: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

The role of endothelin in the pathogenesis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Neurohumoral Activation and Ventricular Arrhythmias in Patients with Decompensated Congestive Heart Failure:

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Neurohormonal inhibition in heart failure: insights from recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Structure-based design and synthesis of novel potent Na+,K+ -ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride].

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Istaroxime: a new luso-inotropic agent for heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effect of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Is the pregnancy hormone relaxin an important player in human heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

The pregnancy hormone relaxin is a player in human heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Perhexiline maleate and peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Risk of death associated with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Classical inotropes and new cardiac enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Evidence-based use of levosimendan in different clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Levosimendan for the treatment of acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Nesiritide — Not Verified

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.01.002

10.1016/J.EJHEART.2008.01.002

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference